Active Biotech AB Interim report January - March 2018
May 17 2018 - 10:00AM
First quarter in
brief
-
Decision on new share issue with preferential
rights for shareholders taken at Extraordinary General Meeting on
March 19, 2018
-
Patent application for tasquinimod for the
treatment of multiple myeloma approved in the US
-
Product patent for the second patent family in
the SILC project granted in the US
Events after the end of the
period
-
The rights issue implemented in April was
oversubscribed by approximately 30 percent. The company received a
capital infusion of approximately SEK 46,9 M after issue
expenses
-
Our partner NeoTX presented new preclinical data
for ANYARA at the AACR Annual Meeting in Chicago
Financial
summary
| SEK M |
Jan-Mar |
Full-year |
| |
2018 |
2017 |
|
2017 |
|
|
|
|
|
|
| Net
sales |
4.8 |
4.7 |
|
20.2 |
| Operating
loss |
-8.5 |
-14.6 |
|
*-102.5 |
| Loss
after tax |
-10.2 |
-15.8 |
|
*-108,8 |
| Loss per
share (SEK) |
-0.11 |
-0.16 |
|
-1.12 |
| Cash and
cash equivalents (at close of the period) |
12.8 |
62.7 |
|
25.2 |
* of which write down of property SEK
50 M
For further information, please
contact:
Helén Tuvesson,
CEO
Tel: +46 (0)46-19 21 56
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
|
Active
Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
|
The report is also available at
https://www.activebiotech.com/en.
Active Biotech AB Interim report
January - March 2018
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024
